Drug Discovery World

MAY 6, 2024

In this article, DDW’s Diana Spencer highlights several prominent hotspots that are taking the lead on advancing European drug discovery and development. The oldest, still active pharmaceutical company worldwide, Merck, started life in 1668 in Darmstadt, Germany. The CDD will sponsor and manage KWF-supported trials. billion ($7.9

Drugs 59

Drugs Life Science Gene Editing Gene 59

XTalks

OCTOBER 4, 2023

Heather McDonald: My previous role at Bayer was a global-level role with a specific focus on cell and gene therapies. In addition, AstraZeneca just announced a major acquisition of Pfizer’s cell and gene therapy portfolio. How is the shift toward value-based healthcare affecting drug pricing and reimbursement?

Marketing 105

Marketing Development Drugs Gene Therapy 105

Drug Discovery World

OCTOBER 4, 2022

DDW Editor Reece Armstrong explores some of the trends that will be featured in sessions throughout ELRIG Drug Discovery 2022 and the news behind them. Cell and gene therapies. There’s no question that cell and gene therapies have emerged as some of the most promising and innovative medicines on the market. .

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

pharmaphorum

NOVEMBER 30, 2020

Cure Rare Disease’s Rich Horgan discusses the importance of preclinical NAbs screening and helping rare disease patients better understand their eligibility for gene therapies. In serious cases, higher levels of pre-existing NAbs can even cause a dangerous immune reaction when such therapies are administered.

Gene Therapy 105

Gene Therapy Gene Antibody Clinical Trials 105

Drug Discovery World

OCTOBER 16, 2023

The United Kingdom has established itself as a hub for drug discovery expertise worldwide. There is a range of reasons why this area has become focal point for drug discovery, one of which is the fact that it encompasses the University of Oxford and the University of Cambridge, two of the oldest and most prestigious universities in the world.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Pharmaceutical Technology

JANUARY 31, 2023

FDA director Robert Califf gave his prognosis for the pharma industry at this year’s JP Morgan Healthcare Conference in San Francisco over January 9–12. That leaves three years for pharma companies to prepare. asked panel chair Ipsita Smolinski, MD of consultancy Capitol Street. Cailiff’s answer was circumspect.

Drugs 130

Drugs Regulation Gene Therapy Insulin 130

XTalks

FEBRUARY 16, 2022

In this episode, Ayesha discussed the NHS’s recommendation of Libmeldy, a gene therapy for the treatment of the rare disease MLD, which is officially the world’s most expensive drug with a list price of almost $4 million USD. Libmeldy was initially rejected by the drug price watchdog NICE in England over its exorbitant price.

Life Science 52

Life Science Gene Therapy Drugs Pharma Companies 52

XTalks

MARCH 28, 2024

Italy-based drugmaker Italfarmaco has won US Food and Drug Administration (FDA) approval for its oral medication Duvyzat (givinostat) for the treatment of Duchenne muscular dystrophy (DMD) in patients six years of age and older. The global incidence of DMD is approximately one in every 3,500 to 6,000 male births.

FDA Approval 105

FDA Approval Genetics Gene Therapy Gene 105

pharmaphorum

JANUARY 24, 2023

Drug development has long been an issue for the pharma industry, due to the expense and the high failure rate of potential treatments. Ben Hargreaves finds that the vast amount of genetic data that exists today could help provide a faster, more targeted way of developing new drug candidates.

Genetics 98

Genetics Drugs Genome Project Biobanking 98

XTalks

DECEMBER 29, 2022

For example, on the pharma and biotech side, there has been growing demand for new drugs and biologics, from new classes of dual-action diabetes and weight loss drugs like Ozempic and Mounjaro to life-saving gene therapies. 1. Cell and Gene Therapies.

Life Science 52

Life Science Gene Therapy Gene Manufacturing 52

pharmaphorum

DECEMBER 14, 2022

Last month we saw some movement in the pharma world, but also in some of the orbiting worlds of agencies, consultancies, and pharma investors. In addition, two team members are taking on new roles at the company, with Glen Webster named EVP of global operations and Jennifer White named global head of growth. New CEO joins UBC.

Life Science 98

Life Science Gene Therapy Gene Editing Gene 98

Drug Discovery World

FEBRUARY 10, 2023

DDW Editor Reece Armstrong explores the Scandinavian drug discovery sector and speaks to key players about Sweden’s place in the market. Testa Center was able to help Lokon Pharma gain a better understanding of the manufacturing process for its oncolytic virus-based gene therapy. It’s also a seal of quality.

Life Science 52

Life Science Drugs Gene Therapy Manufacturing 52

Drug Discovery World

AUGUST 4, 2023

With so many exciting novel treatments emerging from the labs, biotechs and pharma companies need to understand the potential unknowns as well as the known considerations if they are to optimise their impact in the real world. Other challenges involve talent gaps, particularly now that cell and gene therapy manufacturing is maturing.

Gene Therapy 52

Gene Therapy Gene Manufacturing Marketing 52

pharmaphorum

JANUARY 29, 2021

Since that discovery, a flurry of gene-editing focused biopharma companies have launched – including Intellia Therapeutics, CRISPR Therapeutics, Caribou Biosciences and Mammoth Biosciences – and the first drug therapies based on the technology are now in human testing for diseases like cancer. billion in funding.

Gene Editing 145

Gene Editing Gene Gene Therapy In-Vivo 145

Pharmaceutical Technology

JULY 6, 2022

This period of hype saw companies going public earlier, which could explain why we may see some companies being merged or bought out, says Jason Foster, CEO of Ori Biotech, a private cell and gene therapy manufacturing company.

Marketing 324

Marketing Gene Therapy Manufacturing Pharma Companies 324

Drug Discovery World

APRIL 3, 2023

As the industry’s awareness of alternatives to traditional antibodies continues to grow, there is increasing demand for these alternatives, which we are seeing particularly within the therapeutic sector, to enable targeted therapeutics and enable the emerging gene therapy market. DS: The company now has clients across big pharma.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

pharmaphorum

APRIL 21, 2022

One of the leading companies in the bid to bring a new class of alpha-synuclein targeting drugs to market for Parkinson’s disease – AbbVie – is ducking out of the challenge. The post BioArctic left in the cold as AbbVie abandons Parkinson’s pact appeared first on.

Antibody 97

Antibody Protein Gene Therapy Pharma Companies 97

pharmaphorum

DECEMBER 1, 2022

Exploring the implementation of complex in-vitro models for drug development. The pharmaceutical industry globally is realising the growing potential of in vitro tissue models for drug discovery, pathology modelling and validation, safety and toxicity. Billion by 2028. Masato Ohbuchi, Senior Researcher, Astellas. Who Should Attend?

In-Vitro 52

In-Vitro Engineer Scientist Gene Therapy 52

pharmaphorum

SEPTEMBER 22, 2022

Envision’s Rachel Shemer, along with TwoLabs’ Kimberly Cash and Angus Bromley, examine key elements of a successful drug launch. What physicians need from post-pandemic pharma comms. Gene therapies for prevalent diseases in Europe. Moving forward the evolution of digital maturity in pharma. Frontiers Health 2022.

Gene Therapy 52

Gene Therapy Marketing Gene Sales 52

XTalks

DECEMBER 20, 2023

These advancements and trends addressed important industry challenges and offered opportunities to foster innovations and solutions in areas including drug development, healthcare and medical devices. The shortages have been partly blamed on the off-label prescribing of the drugs for weight loss.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59

pharmaphorum

NOVEMBER 22, 2022

Francis, who is currently CEO of gene therapy specialist Purespring Therapeutics and cardiovascular drug developer company Forcefield Therapeutics, is due to take the top job at Teva on 1 January, and will serve as the pharma company’s president. Richard Francis.

Sales 58

Sales Gene Therapy Pharma Companies Gene 58

Drug Channels

FEBRUARY 6, 2024

Drug Channels, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@drugchannels.net). © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

Pharmacy 40

Pharmacy Gene Therapy Pharma Companies Production 40

Pharmaceutical Technology

MAY 24, 2023

By Luisa Sterkel & Joana Loureiro , Tenthpin Consultants The promise and potential of cell and gene therapies (CGT) has emerged in the recent past and currently over 1.500 CGT are registered for clinical trials holding great hope for the treatment of challenging and uncurable diseases.

Clinical Trials 246

Clinical Trials Clinical Trials Gene Therapy Clinical Supply Chain 246

Pharmaceutical Technology

JULY 6, 2022

This period of hype saw companies going public earlier, which could explain why we may see some companies being merged or bought out, says Jason Foster, CEO of Ori Biotech, a private cell and gene therapy manufacturing company. Ori raised over $100 million (EUR97.52

Marketing 162

Marketing Gene Therapy Manufacturing Pharma Companies 162

XTalks

OCTOBER 22, 2020

Pharmaceutical development of novel drugs is a complex and tedious process. The information shared between different multidisciplinary teams is critical to reducing the cost and ultimately accelerating the path of bringing a drug to market.

Manufacturing 98

Manufacturing Development Production Gene Therapy 98

Drug Discovery World

SEPTEMBER 28, 2022

Ben Folwell, Principal Consultant at Citeline, maps out how AI, swarm learning and open access to clinical data could revolutionise drug discovery. . Its application in pharma, most commonly in drug discovery, has been steadily growing with global partnerships between tech vendors and pharma companies becoming more commonplace.

Pharma Companies 52

Pharma Companies Drugs In-Vivo Genetics 52

Pharmaceutical Technology

JUNE 14, 2023

A GlobalData report which analyzes trends in new drug approvals [i] shows that small molecule approvals have now been surpassed (in 2022) by biologics. Biologics form 51% of the current global drugs pipeline (highest stage of development as pipeline) according to GlobalData’s Drugs database (as of February 7, 2023).

Contract Packaging 130

Contract Packaging Packaging Packaging Development 130

Delveinsight

DECEMBER 15, 2020

Gannex received US FDA fast track designation for its NASH drug, ASC42 an FXR Agonist. Gannex Pharma has received Fast Track designation approval from FDA for its drug candidate ASC42 for non-alcoholic steatohepatitis (NASH). Welcome the new entrant in Gene therapy market: InnoSkel.

Vaccination 54

Vaccination Vaccine Gene Therapy Gene 54

pharmaphorum

JUNE 11, 2021

It’s a big disappointment for the specialist in drugs and gene therapies for ocular diseases, although the decision to embark on a COVID-19 programme has been viewed as a somewhat maverick move for the biotech.

Vaccination 83

Vaccination Vaccine Clinical Trials Clinical Trials 83

pharmaphorum

NOVEMBER 30, 2022

The biggest gathering of pharma companies in Europe right now on the commercial side, the Veeva Systems Summit permits the sharing of best practices and of new ideas. Facts that they gleaned included: Across Europe, only 52% of HCPs will accept a visit from a pharma company (i.e.

Life Science 98

Life Science Pharma Companies Sales Marketing 98

pharmaphorum

APRIL 28, 2022

Although they have, by definition, small addressable markets, the treatments cost just as many resources to develop as therapies for more common diseases – sometimes more, because of the added difficulty of finding sufficiently large patient populations for trials and finding disease experts to run them. How big pharma tackles rare diseases.

Pharma Companies 58

Pharma Companies Branding Development Marketing 58

pharmaphorum

NOVEMBER 12, 2020

UCB has made a new foray into the gene therapy space, buying fellow Belgium-based company Handl to get control of its adeno-associated virus (AAV) capsid delivery platform and two research programmes in neurodegenerative diseases. The post UCB revs up its gene therapy drive with Handl acquisition appeared first on.

Gene Therapy 52

Gene Therapy Gene Manufacturing Contract Manufacturing 52

pharmaphorum

SEPTEMBER 29, 2020

As of 2018, there were over 1,100 cancer therapies in development, and as of 2020, 362 of them were cell and gene therapies. Many novel therapies have been successfully developed through such partnerships. Case Study: From Technology Agreement to co-development and co-commercialisation partnership.

Research 132

Research Gene Editing Gene Development 132

Drug Discovery World

MARCH 29, 2023

Politico published a summary of the key propositions outlined in the draft 2 , and DDW’s Multimedia Editor Megan Thomas investigates their intention, and observes how the industry has responded. Key proposals Approved drugs must launch in all EU countries within two years Politico described this as a measure to ensure a level playing field.

Clinical Trials 52

Clinical Trials Clinical Trials Production Medicine 52

pharmaphorum

AUGUST 4, 2021

This SMA Awareness month , we look at how digital health solutions can complement and enhance the effectiveness of drug-based treatments for rare diseases and make a positive difference in the life of patients. This changed with the 2017 release of Biogen’s Spinraza, the first FDA-approved therapy for SMA. About the author.

Gene Therapy 145

Gene Therapy FDA Approval Pharma Companies Development 145

Delveinsight

FEBRUARY 14, 2021

Caretakers and families of patients shell out thousands of dollars yearly to buy orphan drugs, as designated by the USFDA. Pharmaceutical companies sell their orphan drugs at astronomical prices such that many patients are not able to afford them. However unfortunate this is, it can be understood.

Marketing 52

Marketing Clinical Trials Clinical Trials Trials 52

Drug Discovery World

JANUARY 26, 2023

According to research from Deloitte 1 , the average ROI in R&D for global pharma companies fell to just 1.2% The modernisation of R&D models could be key to reducing spend on new drugs, a point that Deloitte makes about the need to transform the clinical trials process. the industry experienced in 2021.

Development 98

Development Drugs Clinical Trials Clinical Trials 98